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TBS	   	   Tris	  buffer	  saline	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	  
TC	   	   Tumor	  cells	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	  
TGF-­‐β	   	   Tumor	  growth	  factor	  beta	   	   	   	   	  
	   	   	   	   	   	   	   	   	  
TUNEL	   	   Transferase	  mediated	  dUTP	  nick-­‐	  end	  labelling	   	   	  
	   	   	   	   	   	   	   	   	  
VEGF	   	   Vascular	  endothelial	  growth	  factor	   	   	   	  
	   	   	   	   	   	   	   	   	  
Vwf	   	   von	  Willebrand	  Factor	   	   	   	   	  
	   	   	   	   	   	   	   	   	  














	   	  Aktiviti	   angiogenesis	   dan	   apoptosis	   memainkan	   peranan	   yang	   penting	   untuk	   perkembangan	  
sesuatu	  kanser.	  Bagaimanapun	  sehingga	  kini	  tiada	  kajian	  yang	  dibuat	  untuk	  mengkaji	  hubungan	  antara	  
keduanya	   di	   dalam	   sel	   kanser	   termasuk	   kaitan	   antara	   kedua	   aktiviti	   ini	   di	   dalam	   sel	   kanser	   dan	   sel	  
endotelium.	  
	   Kajian	   ini	   bertujuan	   untuk	   membandingkan	   ekspresi	   	   protein	   ‘anti-­‐apoptosis’	   Bcl-­‐2	   dan	   ‘pro-­‐
apoptotic’	  Bax	  dalam	  sel	  kanser	  	  dan	  sel	  endotelium	  dalam	  STS.	  Selain	  itu	  kami	  juga	  menentukan	  kaitan	  
antara	  aktiviti	  ‘apoptosis’	  dan	  ‘angiogenesis’	  dalam	  STS.	  	  
	   Kajian	  ‘cross	  sectional’	  telah	  dijalankan	  dari	  	  April	  2009	  hingga	  Oktober	  2010.	  Sebanyak	  101	  kes	  	  
STS	  terlibat	  	  dalam	  kajian	  ini	  seperti	  	  liposarcoma	  (37),	  MFH	  (19),	  synovial	  sarcoma	  (6),	  leiomyosarcoma	  
(14),	  MPNST	  (7),	  fibrosarcoma	  (9)	  dan	  rhabdomyosarcoma(9)	  .	  Potongan	  tisu	  daripada	  	  ‘block’	  tisu	  arkib	  
dikaji	  dengan	  kaedah	  immunohistokimia	  bagi	  menentukan	  ekspresi	  protein	  Bcl-­‐2,	  Bax	  dan	  VEGF.	  
	   Ekspresi	   Bax	   dalam	   sel	   kanser	   (54.5%)	   adalah	   lebih	   tinggi	   daripada	   ekspresi	   Bcl-­‐2	   (44.6%),	  
walaupun	   tidak	   signifikan	   secara	   analisa	   statistik.	   Kami	   juga	   mendapati	   kaitan	   yang	   signifikan	   bagi	  
ekspresi	  	  Bcl-­‐2	  dan	  Bax	  dalam	  sel	  kanser	  dan	  sel	  endothelium	  (p<0.001).	  Bagi	  karektor	  kanser	  pula,	  satu-­‐
satunya	  penemuan	  yang	  signifikan	  adalah	  ekspresi	  Bcl-­‐2	  dengan	  ‘histologic	  subtypes’.	  Dalam	  kajian	  ini	  
kami	   	   dapat	   menunjukkan	   bahawa	   ekspresi	   	   VEGF	   adalah	   tinggi	   apabila	   ekspresi	   Bax	   rendah.	  
Walaubagaimanapun,	   ekspresi	   VEGF	   didapati	   tiada	   kaitan	   dengan	   ekspresi	   Bcl-­‐2,	   lokasi	   kanser,	  
kedalaman	  kanser,	  saiz	  kanser,	  status	  margin	  dan	  status	  nodul	  limfa.	  
	   Kesimpulannya,	  Kajian	   ini	  menyokong	  peranan	  sel	  endotelium	  didalam	  proses	  ‘tumoregenesis’.	  
Oleh	  itu,	  rencatan	  pada	  faktor	  yang	  boleh	  menyebabkan	  survival	  pada	  sel	  endotelium	  selain	  pengaktifan	  
pada	   faktor	   yang	   menyebabkan	   kematian	   sel	   endotelium	   boleh	   menjanjikan	   prospek	   yang	   berguna	  
didalam	   kajian	   terapi	   kanser	   ini.	   Selain	   itu,	   ketiga-­‐tiga	   protein	   yang	   digunakan	   didalam	   kajian	   ini	  
terutamanya	  Bcl-­‐2	  sebenarnya	  berpotensi	  sebagai	  petunjuk	  untuk	  sesuatu	  entiti	  bagi	  membantu	  proses	  
pendiagnosaan	  kerana	  reaksinya	  yang	  berbeza	  untuk	  setiap	  jenis	  ‘histologic	  subtypes’	  didalam	  STS.	  	  
Aktiviti	   ‘angiogenesis’	   yang	   tinggi	   	   berkemungkinan	   merencat	   apoptosis	   pada	   sel	   kanser	   yang	  
menyebabkan	   perkembangan	   luar	   kawalan	   sel	   kenser	   .	   Walaubagaimanapun,	   aktiviti	   ‘angiogenesis’	  
tidak	   bergantung	   kepada	   aktiviti	   ‘anti-­‐apoptosis’.	   Justeru,	   kefahaman	   yang	   mendalam	   berkaitan	  
xiii	  
	  
perhubungan	  antara	  aktiviti	   ‘angiogenesis’	  dan	   ‘apoptosis’	   ini	  boleh	  menjadi	  batu	  loncatan	  untuk	  lebih	  
























EXPRESSIONS	  OF	  ANGIOGENIC	  MARKERS	  AND	  APOPTOIC	  MARKERS	  IN	  SOFT	  TISSUE	  SARCOMA.	  
	  
Dr	  Yusri	  Yusuf	  
MPath	  (Anatomic	  Pathology)	  
	  
Department of Pathology, School of Medical Sciences, Universiti Sains, Malaysia, 16150, 
Kelantan, Malaysia. 
	  
Introduction: For	  tumor	  development	  and	  progression,	  angiogenesis	  and	  apoptosis	  play	  a	  crucial	  role.	  
No	  study	  so	  far	  has	  tried	  to	  associate	  these	  two	  activities	  in	  tumor	  cells	  as	  well	  as	  correlation	  of	  both	  
activities	  in	  the	  tumor	  and	  the	  endothelial	  cells.	  
Aim:	   This	   study	  was	   designed	   to	   compare	   the	   expression	   of	   anti-­‐apoptotic	   Bcl-­‐2	   and	  pro-­‐apoptotic	  
Bax	   on	   the	   tumor	   cells	   and	   the	   endothelial	   cell	   of	   blood	   vessels	   supplying	   the	   tumor	   in	   soft	   tissue	  
sarcoma.	   In	   relation	   to	   that,	   we	   also	   tried	   to	   associate	   the	   relationship	   between	   apoptotic	   and	  
angiogenic	  activity	  in	  soft	  tissue	  sarcoma.	  
Methodology: A	  cross	  sectional	  study	  was	  conducted	  from	  April	  2009	   to	  October	  2010.	  101	  cases	  of	  
soft	  tissue	  sarcoma	  consisted	  of	  liposarcom	  (37),	  MFH	  (19),	  synovial	  sarcoma	  (6),	   leiomyosarcoma	  (14),	  
MPNST	   (7),	   fibrosarcoma	   (9)	   and	   rhabdomyosarcoma	   (9)	   were	   included	   in	   this	   study.	   Tissue	   sections	  
that	  were	  retrieved	  from	  archieved	  tissue	  blocks	  were	  stained	  with	  immunohistochemical	  stain	  for	  Bcl-­‐2,	  
Bax	  and	  VEGF	  protein.	  
Results: Higher	   expression	   of	   Bax	   in	   tumor	   cells	   (54.5%)	  was	   seen	   compared	   to	   expression	   of	   Bcl-­‐2	  
(44.6%)	   though	   statistically	   not	   significant.	   There	   were	   also	   significant	   association	   between	   the	  
expression	  of	  Bcl-­‐2	  and	  Bax	   in	  tumor	  cells	  with	  endothelial	  cells	  (p<0.001).	  With	  tumor	  characteristics,	  
the	   only	   significant	   association	   in	   our	   study	   was	   the	   expression	   of	   Bcl-­‐2	   in	   tumor	   cells	   with	   tumor	  
histologic	  subtypes.	   	   In	  this	  study,	  we	  were	  able	  to	  demonstrate	   that	   the	  expression	  of	  VEGF	   is	  higher	  
with	  weak	  expression	  of	  Bax	  in	  soft	  tissue	  sarcoma.	  However,	  the	  expression	  of	  VEGF	  was	  not	  associated	  
xv	  
	  
with	   expression	  of	   Bcl-­‐2,	   tumor	   location,	   depth,	   size,	  margin,	   lymph	  nodes	  metastases	   and	  histologic	  
subtypes.	  
Conclusion: This	  study	  supports	  the	  role	  of	  endothelial	  cells	   in	  survival	  and	  regression	  of	  tumor	  cells	  
in	  tumoregenesis.	  Thus,	  the	  inhibition	  of	  endothelial	  cells	  survival	  factor	  or	  activation	  of	  endothelial	  cells	  
death	   is	  a	  promising	  prospect	  as	  a	   candidate	   for	   tumor	   therapy.	   	    All the proteins used in this study 
might be potential as a useful marker for diagnosis of specific histologic subtypes especially Bcl-2	  since	  
there	  is	  diversity	  in	  expression	  amongst	  the	  various	  histologic	  subtypes	  in	  STS.	  An	  increase	  in	  angiogenic	  
activity	   may	   inhibit	   apoptotic	   tumor	   cells	   death	   which	   leads	   to	   cell	   proliferation.	   However,	   the	  
angiogenic	   activity	   was	   independent	   of	   anti-­‐apoptotic	   activities.	   A	   better	   understanding	   of	   their	  
relations	  probably	  provides	  the	  basis	  for	  more	  rational	  cancer	  therapies	  in	  the	  future.	  
	  
Dr Thin Thin Win @ Safiya: Supervisor 




















































Soft tissue sarcomas are rare diseases that encompass a histologically and anatomically diverse 
group of neoplasm, which share a common embryologic origin from mesodermal tissue. 
Despite the relative rarity with annual incidence about 30/million, i.e. less than 1% of all 
malignant tumors but there is an increase in incidence and mortality trend, posing a significant 
diagnostic and therapeutic challenge due to their heterogeneity. In Malaysia, the tumor shows 
a slightly decreasing trend for newly diagnosed cases of cutaneous, subcutaneous and soft 
tissue sarcoma in both sex for Peninsular Malaysia, representing about 133 (1.4%) for male and 
115 (1%) for female in year 2003 (National Cancer Registry, 2004) as compared to about 130 
(0.6%) for male and 106 (0.5%) for female in 2006 (National Cancer Registry, 2006).  
 
For tumor development and progression, many researchers have been looking into the 
apoptotic and angiogenic activities of cancer cells. Apoptosis activity depends partly on the 
balance between Bcl-2 which is anti-apoptotic and Bax which is pro-apoptotic gene expression. 
Most studies found that over-expression of Bcl-2 correlates with histological types, histological 
grades and prognosis. In previous studies, the Bcl-2 expression were 43% (Nakanishi. et al., 
1997), 38.8% (Sabah. et al., 2007) and 32.2% (Tomoyoki. D. et al., 2002 ) whereas Bax 
expression were 92.8% (Sabah. et al., 2007) and 40.8% (Tomoyoki. D. et al., 2002). Common 
immunoreactivity are seen in synovial sarcoma and MPNST (Kawauchi. S. et al. 1999 and Sabah. 
et al. 2007). Therefore, it may aid in differential diagnosis in synovial sarcoma (Suster. et al., 
1997). In relation to the histologic grade and prognosis, the study by Sabah. et al 2007 revealed 
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the overexpression of Bcl-2 in high grade sarcoma may used as poor prognostic marker. In 
contrast, the study by Nakanishi. et al. 1997 showed the opposite view as the stronger Bcl-2 
were associated with favourable prognosis whereas no correlation of both reported by 
Tomoyuki. D. et al. 2002 Only 2 studies have evaluated Bax expression in STS by 
immunohistochemistry. In this study, Bax expression was a common finding in STS (Kawauchi. S. 
et al., 1999 and Tomoyoki. D. et al.,  2002) and no correlation with Bcl-2 and tumor grade was 
identified (Tomoyoki. D. et al., 2002and Sabah. et al., 2007). No study has been done on the 
expression of apoptotic marker in endothelial cells of blood vessel supplying the tumor. Hence 
one of our objectives is to look into this matter and correlate the findings with the expression of 
these markers in the tumor cells. 
 
In relation to that, we will also study the angiogenic activities of the cancer cells as well as 
endothelial cells. The importance of angiogenesis in tumor progression and metastasis is well-
recognized and its potential role in prognosis and therapeutic application has lead to many 
ongoing clinical researches. Angiogenesis can be studied by looking at the expression of 
angiogenetic markers such as vascular endothelial growth factor (VEGF) and hypoxia inducible 
factor 1α (HIF-1α). HIF-1 is heterodimer consisting of α and β subunits. HIF-1α expression is 
related to cellular hypoxia, whereas HIF-1β subunit is constitutively expressed independent of 
cellular hypoxia. HIF-1α is transcription factor that stimulate VEGF transcription and support 
the tumor growth and progression (Shintani. K. et al., 2006). VEGF expression was diverse 
amongst the various histological subtypes. Leiomyosarcoma, synovial sarcoma and MFH were 
the more likely to over express VEGF than other histological types (Chao. C. et al. 2001, Potti A. 
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et al 2004. and Hong. T. et al., 2001). The expression of VEGF in STS was 75% by Chao. C. et al., 
2001 but the expression was very low (25%) by Potti A. et al. 2004. The expression of HIF-1α 
was 71.4% by Shintani. K. et al., 2006. However many studies showed no relationship between 
survival and VEGF status except for leiomyosarcoma as high VEGF was associated with shorter 
survival (Potti. A. et a.,l 2004). Microvessel density (MVD) is the best option for better 
quantitation of the angiogenetic activity. However after considering time limit, an evaluation of 
the VEGF to represent angiogenesis was considered more practical for this study. 
 
No clinical study has correlated angiogenic and apoptotic activities in cancer cells. All of the 
studies on apoptosis and angiogenesis of STS so far were done separately. We attempt to do 
this and at the same time looking at the apoptotic and angiogenic activities in the tumor cell as 



























2. LITERATURE REVIEW 
2.1. General 
Soft tissue tumors are defined as mesenchymal proliferations that occur in the extraskeletal, 
nonepithelial tissues of the body excluding the viscera, coverings of the brain and 
lymphoreticular system (Robbin and Cotran, 2004).  
 
Soft tissue sarcoma (STS) is a heterogenous group of malignant tumor that is traditionally 
classified based on a histogenetic basis according to the adult tissue they recapitulate. The new 
WHO classification of Soft tissue tumors 2002 incorporates detailed clinical, histological and 
genetic data. According to the WHO classification 2002, soft tissue sarcomas are classified as 
follows: 
Table 2.1: WHO Classification of Soft Tissue Sarcoma 2002. 
No. Group Tumors 




3. Fibrohistiocytic tumors Malignant Fibrous Histiocytoma (MFH) 
4. Skeletal muscle tumors Rhabdomyosarcoma 
5. Smooth muscle tumors Leiomyosarcoma 
6. Vascular tumors Angiosarcoma and  
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epithelioid hemangioendothelioma 
7. Chondro-osseous tumors Mesenchymal chondrosarcoma and extraskeletal 
osteosarcoma.  
8. Tumors of uncertain 
differentiation 
Synovial sarcoma, epitheliod sarcoma, alveolar soft 
part sarcoma, clear cell sarcoma, extraskeletal 
myxoid chondrosarcoma, PNET/extraskeletal Ewing 
tumor, desmoplastic small round cell tumors, 
extrarenal rhabdoid tumor, malignant 
mesenchymoma, neoplasms with perivascular 




However, there is an evolving classification of soft tissue sarcoma. In the most recent WHO 
Classification, so-called pleomorphic MFH is no longer regarded as a definable tumor type, but 
instead is synonymous with undifferentiated pleomorphic sarcoma, a diagnosis of exclusion for 
no more than 5% of adult sarcomas. It is now widely agreed that these tumors show no evidence 
of true histiocytic differentiation.  
 
Following the creation of the prototypical form of MFH, the storiform-pleomorphic variant and 
other MFH variants were generated. So-called myxoid MFH is now termed myxofibrosarcoma to 
underline the fibroblastic line of differentiation of this neoplasm while so-called angiomatoid 
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MFH, undoubtedly a discrete entity, is now reallocated to the category of tumors of uncertain 
differentiation.  
 
Similarly, the overwhelming majority of lesions formerly labelled inflammatory MFH are 
nowadays recognized to be dedifferentiated liposarcoma as a result of recent molecular analysis 
of the 12q13-14 chromosome region in a large series of retroperitoneal ‘inflammatory MFH’. 
Some of the cases diagnosed as such in the past actually represented lymphomas of both 
Hodgkin and non-Hodgkin types, leiomyosarcomas and sarcomatoid carcinomas. Besides that, 
most example of so-called giant cell MFH are re-classified as either giant cell-rich 
osteosarcomas, giant cell tumor (osteoclastoma) of soft tissue, leiomyosarcoma with an 
osteoclastic giant cell reaction or as giant cell-rich anaplastic carcinoma. 
 
Currently, accurate subclassification of pleomorphic sarcomas is mandatory as it enables 
recognition of non-sarcomatous lesions as well as pleomorphic neoplasm not associated with 
aggressive behavior. Furthermore, as myogenic differentiation predicts aggressive clinical 
behavior among pleomorphic sarcomas, precise histotyping allows prognostic stratification of 
patients. (Dei Tos A.P. et al. & Fletcher C.D.M., 2006). 
 
By convention, the soft tissue sarcomas also include the peripheral nervous system because 
tumors arising from nerves present as soft tissue masses and pose similar problem in differential 
diagnosis and therapy. Embryologically, soft tissue is derived principally from mesoderm, with 
 9 
some contribution from neuroderm (Enzinger and Weiss’e et al., 2008). Therefore in most of the 
soft tissue sarcoma studies, the MPNST was also included. 
 
In general, there is only very slight preponderance of STS in males compare to females and more 
common in older patient (Enzinger and Weiss’s et al., 2008). The mean age is 65 years. However, 
the age-related incidences vary; embryonal rhabdomyosarcoma occurs almost exclusively in 
children and synovial sarcoma develop in late adolescence and young adulthood, whereas 
pleomorphic high grade sarcoma and liposarcoma dominate in the elderly (WHO, 2004) 
  
STS can occur in any anatomical location but three fourths are located in the extremities (most 
common in thigh) and 10% each in the trunk wall and retroperitoneum. Of the extremity and 
trunk, one-thirds is superficial with median diameter of 5cm and two-thirds are deep seated with 
a median diameter of 9cm. Retroperitoneal tumor are often much larger before they become 
symptomatic and one tenth of the patients have detectable metastases (most common in the lung) 
at diagnosis of the primary tumors. (WHO, 2004) 
 
The pathogenesis of most soft tissue tumors is still unknown.  Most of these cancers had no 
clearly defined cause but several infrequent predisposing factors have been described such as 
genetic predisposition (mainly Recklinghausen diseases and bilateral retinoblastoma) and 
iatrogenic factors such as post-irradiation and postoperative chronic lymphoedema (Levi.F. et al., 
1999). MFH and angiosarcoma are the most common histological subtype of radiation-induced 
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STS. Radiation induced STS are usually high grade and developed at the peripheral borders of 
radiation fields (Brady M.S. et al., 1992). The Stewart-Treves syndrome represents about 5% of 
all angiosarcomas (Roy P. et al. 2004, Kirova Y.M. et al. 2007 and Harvey E.B. et al. 1985). 
Recent study shows that 2.8% of STS are related to genetic syndrome (Penel N. et al., 2008). 
Recklinghausen neurofibromarosis and bilateral retinoblastoma predominate. About 5% of 
patient affected by Recklinghausen neurofibromatosis develop MPNST. In contrast, recent study 
by Penel N. et al. 2008 revealed that most cases of adult STS are not related to well-established 
risk factors (radiation, genetic deseases and chronic lymphedema). However, in this study the 
diagnosis of genetic syndromes were based on clinical criteria. A systematic genetic testing can 
possibly modify those results. (Penel N. et al., 2008).  
 
The two most widely used grading system for STS are the NCI system (United States National 
Cancer Institute) and the FNCLCC system (French Federation Nationale des Centre de Lutte 
Contre le Cancer). Guillou L. et al. 1997 performed a comparative study on both systems which 
showed both systems were of good prognostic value although grade discrepancies were observed 
in 34% of the cases and the use of the FNCLCC resulted in a better correlation with overall and 
metastases-free survival. (Guillou L. et al., 1997). Besides that, the FNCLCC is more universally 
used because it is more precisely defined and reproducible. (Golouh R. et al, Bracko M. et al. 
2001). For Paediatric sarcoma, a separate grading system has been developed and appears to be 




Table 2.2: Paediatric Oncology Group Soft Tissu Sarcoma Grading System. 
Grade I 
Myxoid and well-differentiated liposarcoma 
Deep seated dermatofibrosarcoma protuberans 
Well-differentiated or infantile (<4 yr old) fibrosarcoma or hemangiopericytoma 
Well-differentiated malignant peripheral nerves sheath tumor 
Extraskeletal myxoid chondrosarcoma 
Angiomatoid (malignant) fibrous histiocytoma 
 
Grade II 
Sarcomas not specifically included in grades I and II and in which < 15% of the surface area 
shows necrotic and the mitotic count is <5 per 10hpf using a 40x objective; as secondary criteria, 
nuclear atypia is not marked and the tumor is not markedly cellular 
 
Grade III 
Pleomorphic or round cell liposarcoma 
Mesenchymal chondrosarcoma 
Extraskeeletal osteosarcoma 
Malignant triton tumor 
Alveolar soft part sarcoma 
Sarcomas not included in grade I and in which >15% of the surface area shows necrosis or the 
mitotic count is >5 mitoses per 10hpf using a 40x objective 






The major staging system for STS was developed by the International Union against Cancer 
(UICC) and American Joint Committee on Cancer (AJCC). This TNM system incorporates 
histological grade, tumor size and depth, regional lymph nodes involvement and distant 
metastases appear to be clinically useful and prognostic value.  
 
The rapid advances in the molecular genetics understanding of soft tissue sarcomas show 
distinctive cytogenetic aberrations, most often reciprocal chromosomes translocations which are 
relatively tumor specific and thus diagnostically useful. (Hahn H.P. et al. 2005 and Antonescu C 
R. et al., 2006).  The well-characterized chromosomal abnormalities in soft tissue sarcomas are 
shown in table 2.3. Unfortunately, many of the more common sarcomas (the high grade spindle 
cell and pleomorphic sarcomas of later adulthood) have complex karyotypes without histotype-
specific features. (Mertens F. et al. and Fletcher C.D.M. et al., 1998).  Overall, abnormal cell 
populations can be detected by either cytogenetics or DNA ploidy studies in about 85% of all 
soft tissue sarcomas. (Mohamed  A.N. et al., 1997). 
Table 2.3: Cytogenetic aberrations in soft tissue sarcomas. 
Tumor type Cytogenetic changes Gene rearrangement 
Ewing’s sarcoma/ peripheral 




















Synovial sarcoma t(X;18)(p11.2;q11.2) SSX1-SYT 
SSX2-SYT 
Dermatifibrosarcoma 
protuberans/ giant cell 
fibroblastoma 
t(17;22)(q22;q13) PDGFB-COL1A1 
Infantile fibrosarcoma t(12;15)(p13;q25) ETV6-NTRK3 
Alveolar soft part sarcoma t(X;17)(p11;q25) ASPL3FE-T 
Low-grade fibromyxoid sarcoma t(7;16)(q33;p11) FUS-CREB3L2 
Angiomatoid MFH  ATF-1 rearrangement 
Atypical lipomatous tumor/ well-
differentiated liposarcoma 




Many studies have been designed to investigate the prognostic factors of soft tissue sarcomas. 
The overall grade and stage (including size) of soft tissue sarcomas, however determined, are the 
most significant prognostic factors (Costa J. et a.l 1984, Guillou L. et al. 1997 and Parham D.M. 
et al., 1995). Age of patient and assessment of the surgical margins are also important (Li X.Q. et 
al., 1996). Patients who presented with positive margins or a margin of 2mm or less had a worse 
survival than patients who had margins of greater than 2mm and wide margin, 5year survival, 
47% versus 70% and 72% ( Novais et al. 2010). Study by S. Vraa et al. 1998 shows the 5year 
local recurrence rate was 18% and the 5year survival rate was 75%.  
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Some investigators have focused their studies on immunohistochemical method. Among them, 
reductions in the expression of E-cadherin and catenins, proteins that are essential for forming 
intercellular junctions, were reported as prognostifications of a poor outcome in patients with 
soft tissue sarcoma, implying that decreases in cell to cell adhesion may cause tumor cell 
dissemination (Heslin M.J. et al., 1998). Ch’ng E.S. et al. 2007 revealed that CD100 expression 
and tumor sizes (<5cm and >5cm) were independent prognostificators for overall survival and 
CD100 expression was an independent prognostificator for disease free survival. We are 
interested in elaborating on angiogenetic and apoptotic marker expression in soft tissue sarcoma 
for further study to associate with prognostification.  
 
2.2 Angiogenesis and apoptosis 
2.2.1 General 
Angiogenesis, the development of new blood vessels from the endothelium of the existing 
vasculature, is a multistage process whereby the angiogenic endothelial cells must proliferate, 
produce molecules able to degrade the extracellular matrix, change their adhesive properties, 
migrate, avoid apoptosis and finally, differentiate to new vascular tubes. All these processes are 
controlled by the signals received by endothelial cells from their environment, signals whose 
transduction pathways form cascades leading to gene transcription and a network of cross-talks 
determining the final behaviour of the cell. The pathways leading to entry into the cell cycle 
depend on the angiogenic signals received (fig. 2.1). Among them, binding of VEGF to the 
endothelial-specific receptor VEGFR2 is the main extracellular signal triggering an angiogenic 
response which leads to proliferation of the endothelium. 
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Figure 2.1: Main signaling pathways involved in proliferation of angiogenic endothelial cells. 
 
Apoptosis is a normal process of programmed cell death involved in morphogenesis, vascular 
remodeling and elimination of neurons or cells from the immune system. Apoptosis seems to be 
essential in initiation of the angiogenic process (Nor J.E. et al., 1999). Caspases, a family of 
cysteine proteases, regulate apoptosis and it is controlled by apoptosis promoting and inhibitory 
factors (Adam J.M. et al., 2001). Angiogenic cells degrading the extracellular matrix should 
reinforce the mechanisms of apoptosis inhibition to avoid the risk of anoikis, i.e. apoptosis 
induced by lack of adhesion to the substrate (Frisch S.M. et al., 1997). For that reason, signals 
inducing endothelial cell migration must also promote cell survival. Endothelial cells repress 
their apoptogenic program through two main signaling pathways initiated from integrin-mediated 




Figure 2.2: Main signaling pathways involved in survival of angiogenic endothelial cells. 
 
Focal adhesions are specific areas of the cell surface where they are the origin of signals that 
activate or inhibit cellular processes such as proliferation, survival and migration of endothelial 
cells (fig. 2.3). The cytoskeletal changes associated to the formation of focal adhesions involve 
the development of stress fibers, lamellipodia and filopodia. These changes are mainly regulated 
by the members of the Ras superfamily of small GTPases RhoA, Rac and Cdc42. They control 
the cytoskeletal dynamics and also the cadherin function in endothelium (Van Wetering S. et al., 
2003). Rho and Rac are essential in the development of endothelial motility induced by VEGF 
(Soga Net et al., 2001) and also control the mechanisms of polarization and migration in 
response to blood flow (Wojeiak-Stothard B. et al., 2003). 
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Figure 2.3: Main signaling pathways involved in migration of angiogenic endothelial cells. The yellow box 






Migration of endothelial cells is finally achieved by controlled cell adhesion, cytoskeletal 
reorganization and localized degradation of the extracellular matrix. In fact, the degradation of 
the basal lamina of the endothelium is one of the earliest events in angiogenesis. Degradation of 
the extracellular matrix is performed by a proteolytic arsenal exquisitely regulated (figure 2.4).  
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Figure 2.4:  Main signaling pathways involved in extracellular matrix degradation induced by angiogenic 
endothelial cells. 
 
After proliferation and migration, endothelial cells should be able to recover quiescence, produce 








Despite the high specificity of the signaling system triggering an angiogenic response in 
endothelial cells, there are no specific signaling pathways or transcription factors regulating the 
entire angiogenic process or any of its stages (Sonein F. et al., 1999). That means that regulation 
of endothelial behavior during angiogenesis is the result of a very complex network of 
intracellular signaling systems that trigger, control and terminate the process. This is expected 
from a process leading to a radical transformation in a cell type that is extraordinarily stable in 
the absence of the angiogenic signal. Knowledge of this network may be at least as necessary 
and useful as the knowledge of the extracellular signals which initiate angiogenesis in order to 
find angiogenic inhibitors or activators with therapeutic utility. It is important to emphasize that 
several angiogenic signaling pathways, such as the MAP kinases or the PI3K/Akt cascades, are 
shared with those leading to tumor cell proliferation and invasion. It should not be surprising that 
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future angiogenic inhibitors able to interfere with some intracellular signaling pathway also 
exhibit antitumoral activity.   
 
 
2.3 Role in tumor development 
Neovascularisation is a requirement for solid tumour growth beyond 1–2 mm in diameter 
(Folkman J. et al., 1991). Blood vessels play an important role in tumorigenesis supplying 
nutrients and oxygen, disposing of metabolic waste products and allowing metastatic spread. 
Tumour growth is dependent on the balance between increasing cell numbers through 
proliferation and decreasing numbers through apoptosis and necrosis (Holmgren L. et al., 1995). 
Potentially a small genetically unstable hypoxic tumour exposed to a hostile environment will 
develop mutations eventually producing a phenotype able to resist apoptosis and therefore have a 
survival advantage (Harris A.L. et al., 1997). 
 
 
The angiogenic process is a balance between stimulatory and inhibitory factors. A change that 
favours stimulation may trip an ‘angiogenic switch’ allowing the tumour to induce the formation 
of microvessels from the surrounding host vasculature (Hanahan et al., 1996). These regulatory 
factors may be endocrine, coming from the circulation, paracrine, from the adjacent tumour, 
stromal and inflammatory cells or extracellular matrix (ECM) and:or autocrine, from the 
endothelial cells themselves.  Tumours promote angiogenesis by secreting or inducing the 
release of growth factors that stimulate endothelial cell migration and proliferation, proteolytic 
activity and capillary morphogenesis. There may be inhibition or loss of the synthesis of 
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antiangiogenic factors, such as thrombospondin-1, that suppress normal angiogenesis (Weinstat 
Saslow D.R. et al., 1994). 
 
 
Apart from being spatially and temporally restricted, microvascular endothelial cells behave in a 
similar manner to invasive tumour cells. Hypoxia and hypoglycaemia induce local proangiogenic 
cytokines and growth factors leading to changes within endothelial cells. There is an increase in 
adhesion molecule expression and release of proteolytic enzymes. Plasminogen activators and 
collagenases create a gap in the basement membrane through which endothelial cells from post-
capillary parent venules migrate into the perivascular stroma and form a capillary bud. Further 
proteolysis of the ECM produces chemotactic degradation products and releases bound growth 
factors. The capillary bud undergoes cell proliferation and sprout extension before maturation 
and lumen formation. The endothelial cells in these new vascular loops are abnormal in shape 
and size with wide cell junctions and an irregular, leaky basement membrane. These new vessels 
leak plasminogen, fibrinogen and platelets leading to extravascular fibrin deposition and 
hypercoaggulation. Inflammation plays an important part in tumorigenesis (Polverini P.J. et al., 
1984) and macrophage infiltration also correlates with angiogenesis (Leek R.D. et al., 1996). 
Overall, growth factors play a crucial role in angiogenesis and malignancy (Fig. 2.6). Growth 
factors secreted by tumour, inflammatory and stromal cells bind to soluble growth factor 
receptors in the stroma (Hannekan A. et al., 1995) where they can be released by proteolytic 
enzymes secreted by an invading tumour. Growth factors may be chemotactic and mitogenic, 
targeting kinase receptors expressed by endothelial and tumour cells. Tumour cell growth factor 
production will lead to self-proliferation and indirectly mediate growth by stimulating tumour 
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vessel proliferation.  Several growth factors have been investigated in soft tissue sarcoma. This 
review will concentrate on the growth factors that have been studied most closely in relation to 
angiogenesis. 
 
Figure 2.6: Growth factors and the induction of angiogenesis. GFs, growth factors; PAIs, plasminogen 
activator inhibitors; TSP-1, thrombospondin-1. 
 
 
The VEGF family consists of VEGF, placental growth factor and VEGF-B, -C, -D and –E. 
VEGF binds with high affinity to two tyrosine kinase receptors, VEGFR-1 (Flt-1) (Hannekan A 
et al., 1995) and VEGFR-2 (Flk-1:KDR) (Terman B I et al., 1992). VEGF is the most potent and 
specific growth factor for endothelial cells. Hypoxia is a common finding in tumours. Hypoxia 
increases VEGF expression (Shweiki D. et al., 1992) by inducing VEGF transcription via 
hypoxia-inducible factor-1a (Brigstock D.R. 2002) and by stabilizing VEGF mRNA (Levy A.P. 
et al 1996). Hypoxia also increases the synthesis of VEGF receptors (Walten Berger J. et al., 
1996). Wild-type p53 down-regulates VEGF promoter activity (Mukhopadhyay D et al., 1995) 
whilst mutant p53 has the opposite effect (Keiser A et al., 1994).  Vascular permeability is 
increased by VEGF allowing tumour dissemination into the circulation and the leakage of 
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plasma proteins and fibrin deposition into the ECM (Dvorak H.F. et al., 1995) that lead to 
activation of proteases and allows ECM degradation. Transfection of VEGF cDNA leads to an 
increase in tumour growth, vascularity and metastases (Senger D.R. et al., 1994-95) and this 
effect can be inhibited using VEGF antibodies (Kondo S et al 1993 and Zhang H.T. et al., 1995). 
The ability of tumour cells to produce VEGF may lead to resistance to apoptosis and therefore 
tip the balance in favour of proliferation and tumour growth. 
 
 
VEGF tumour immunostaining is usually cytoplasmic especially in the perinuclear region. High 
levels of expression of VEGF and their receptors are found in many solid tumours including 
breast (Brown L.F. et al., 1993), colon (Brown L.F. et al., 1993), ovary (Olson T.A. et al., 1994), 
cervix (Guidi A.J. et al., 1995), kidney (Brown L.F. et al., 1993) and non-small cell lung 
carcinoma (Mattern J. et al., 1995, Holm C. et al., 1996, Onta Y. et al. 1996 and Takanami I. et 
al. 1987). There is diversity seen in VEGF expression amongst the various histologic subtype of 
STS whereby leiomyosarcoma, carcinosarcoma and MFH are more likely to reveal 
overexpression of VEGF than the other histologic subtype but no relationship between survival 
and VEGF status in any subtypes of STS, except leiomyosarcoma  ( Potti A. et al., 2005). High 
intensity VEGF expression in soft tissue sarcomas are correlates with advanced tumor grade 
(Chao C. et al. 2001 and Pakos E.E. et al. 2005). Mutation of p53 is very frequently found in soft 
tissue sarcoma and this may also play a role in up-reulating VEGF (Zhang I. et al., 2000). 
 
Neoplastic transformation is brought about through the activation of oncogenes or the 
inactivation of tumour suppressor genes. Lung cancer is associated with the expression of several 
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of these genes including p53, bcl-2, myc, ras and Rb (Sekido Y. et al., 1998). The rate of tumour 
growth is defined by the balance between cell proliferation and cell loss by necrosis and 
apoptosis (programmed cell death). Successful tumour therapies largely rely on an induction of 




Figure 2.7: p53, bcl-2 and apoptosis. P53-P_phosphorylated p53. 
 
Bcl-2 is a member of a family of genes involved in the regulation of apoptosis which includes 
proapoptotic and antiapoptotic proteins such as Bax proteins and Bcl-2 proteins respectively. The 
ratios of different family members seem to determine the survival or death of cells after 
apoptotic stimuli (Oltvai ZN et al., 1993). The bcl-2 gene differs from conventional oncogenes 
as it can neither promote growth nor directly lead to cellular transformation. Raised bcl-2 levels 
protect from the induction of apoptosis by wild-type p53 (Chiou S.K. et al., 1994) whilst p53 
down-regulates bcl-2 gene-expression (Miyashita T. et al., 1994).  The Bcl-2 expression was 
